Licensing is a required step in the pharma industry, and unfortunately, it can be incredibly complicated. The consequences for not carrying the correct license can range from fines to an immediate stop in sales to felony charges – and that’s just the beginning.
Two Labs, an industry-leading pharma and life science services company, announced at Asembia’s 2018 Specialty Pharmacy Summit that Anita Dopkosky, a pharmaceutical industry executive, has joined the Commercialization team as Vice President of Specialty Pharmacy.
Two Labs, an industry-leading pharma and life science services company, today announced that it has acquired MKO Global Partners (MKO), a strategic global life sciences consulting firm focused on payer strategy, market access, and pricing in the pharmaceutical and biotech markets.
Excellere Partners, a Denver-based private equity firm focused on partnering with entrepreneurs and management teams, announced today that it has made a strategic investment in Two Labs Marketing, a leading provider of product commercialization solutions to pharmaceutical manufacturers, offering strategic consulting and implementation services throughout the full product lifecycle.
The Drug Supply Chain Security Act (DSCSA), passed in November 2013, has become a buzzword in the pharma industry in the past few years, and will continue to be until the completion of the implementation in 2023.
The results of these searches tend to center around licensing: in-licensing, out-licensing, drug licensing, and facility licensing. How does all of this relate to launching a drug?
In the pharmaceutical industry, a "Price Book" is often synonymous with Compendia data. Even though physical publications were discontinued more than 15 years ago, people in the industry still use the term "Price Book."
Electronic prescribing allows healthcare providers to manage prescriptions electronically, making prescriptions safe, convenient and fast (SureScripts).
But what if there’s an issue with your new product launch?
